CRISPR/Cas9 tech agreement for corneal blindness cell therapies
ERS Genomics, a CRISPR/Cas9 licensing company, and StemSight, a biotechnology company developing stem cell based therapies for corneal blindness, have entered a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio. StemSight is a preclinical biotechnology company developing off-the-shelf cell therapies for… Read More